Protalix Biotherapeutics (PLX) stock has fallen -45.76% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives PLX stock a score of 75 out of a possible 100.
That score is primarily influenced by a fundamental score of 88. In addition to the average rating from Wall Street analysts, PLX stock has a mean target price of $2.05. This means analysts expect the stock to add 540.63% over the next 12 months. PLX's score also includes a short-term technical score of 86. The long-term technical score for PLX is 52.
Click Here to get the full Stock Score Report on Protalix Biotherapeutics Inc (PLX).
What's Happening with PLX Stock Today
Protalix Biotherapeutics Inc (PLX) stock has risen 76.8% while the S&P 500 is up 0.26% as of 11:14 AM on Thursday, Oct 17. PLX is up $0.14 from the previous closing price of $0.18 on volume of 20,302,508 shares. Over the past year the S&P 500 is higher by 6.68% while PLX has fallen -45.76%. PLX lost -$1.34 per share in the over the last 12 months.